{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T19:54:09Z","timestamp":1792958049095,"version":"4.5.0"},"reference-count":58,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Agonist medications for opioid use disorder (MOUD), buprenorphine and methadone, in carceral settings might reduce the risk of postrelease opioid overdose but are uncommonly offered. In April 2019, the Massachusetts Department of Correction (MADOC), the state prison system, provided buprenorphine for incarcerated individuals in addition to previously offered injectable naltrexone.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate postrelease outcomes after buprenorphine implementation.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study with interrupted time-series analysis used linked data across multiple statewide data sets in the Massachusetts Public Health Data Warehouse stratified by sex due to differences in carceral systems. Eligible participants were individuals sentenced and released from a MADOC facility to the community. The study period for the male sample was January 2014 to November 2020; for the female sample, January 2015 to October 2019. Data were analyzed between February 2022 and January 2024.<\/jats:p><\/jats:sec>Exposure<\/jats:title>April 2019 implementation of buprenorphine during incarceration.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Receipt of MOUD within 4 weeks after release, opioid overdose, and all-cause mortality within 8 weeks after release, each measured as a percentage of monthly releases who experienced the outcome. Segmented linear regression analyzed changes in outcome rates after implementation.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 15\u202f225 individuals were included. In the male sample there were 14\u202f582 releases among 12\u202f688 individuals (mean [SD] age, 35.0 [10.8] years; 133 Asian and Pacific Islander [0.9%], 4079 Black [28.0%], 4208 Hispanic [28.9%], 6117 White [41.9%]), a rate of 175.7 releases per month; the female sample included 3269 releases among 2537 individuals (mean [SD] age, 34.9 [9.8] years; 328 Black [10.0%], 225 Hispanic [6.9%], 2545 White [77.9%]), a rate of 56.4 releases per month. Among male participants at 20 months postimplementation, the monthly rate of postrelease buprenorphine receipt was higher than would have been expected under baseline trends (21.2% vs 10.6% of monthly releases; 18.6 additional releases per month). Naltrexone receipt was lower than expected (1.0% vs 6.0%; 8.8 fewer releases per month). Monthly rates of methadone receipt (1.4%) and opioid overdose (1.8%) were not significantly different than expected. All-cause mortality was lower than expected (1.9% vs 2.8%; 1.5 fewer deaths per month). Among female participants at 7 months postimplementation, buprenorphine receipt was higher than expected (31.6% vs 9.5%; 12.4 additional releases per month). Naltrexone receipt was lower than expected (3.4% vs 7.2%) but not statistically significantly different. Monthly rates of methadone receipt (1.1%), opioid overdose (4.8%), and all-cause mortality (1.6%) were not significantly different than expected.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of state prison releases, postrelease buprenorphine receipt increased and naltrexone receipt decreased after buprenorphine became available during incarceration.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.2732","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T15:36:16Z","timestamp":1710776176000},"page":"e242732","source":"Crossref","is-referenced-by-count":21,"title":["Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes"],"prefix":"10.1001","volume":"7","author":[{"given":"Benjamin J.","family":"Bovell-Ammon","sequence":"first","affiliation":[{"name":"Departments of Medicine and of Healthcare Delivery and Population Sciences, Baystate Health, Springfield, Massachusetts"},{"name":"Department of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shapei","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon","family":"Dunn","sequence":"additional","affiliation":[{"name":"Massachusetts Department of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Health Promotion and Policy, University of Massachusetts Amherst School of Public Health & Health Sciences, Amherst"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Friedmann","sequence":"additional","affiliation":[{"name":"Office of Research and Department of Medicine, University of Massachusetts Chan Medical School\u2014Baystate and Baystate Health, Springfield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Y.","family":"Walley","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"LaRochelle","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"zoi240126r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109655","article-title":"Overdose and substance-related mortality after release from prison in Washington State: 2014-2019.","volume":"241","author":"O\u2019Connor","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"zoi240126r2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.7326\/0003-4819-159-9-201311050-00005","article-title":"Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009.","volume":"159","author":"Binswanger","year":"2013","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi240126r3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMsa064115","article-title":"Release from prison\u2013a high risk of death for former inmates.","volume":"356","author":"Binswanger","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi240126r4","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/add.2010.105.issue-9","article-title":"Meta-analysis of drug-related deaths soon after release from prison.","volume":"105","author":"Merrall","year":"2010","journal-title":"Addiction"},{"key":"zoi240126r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107997","article-title":"Opioid overdose death following criminal justice involvement: linking statewide corrections and hospital databases to detect individuals at highest risk.","volume":"213","author":"Krawczyk","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi240126r6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2105\/AJPH.2021.306621","article-title":"Opioid overdose deaths among formerly incarcerated persons and the general population: North Carolina, 2000\u20132018.","volume":"112","author":"Ranapurwala","year":"2022","journal-title":"Am J Public Health"},{"issue":"3","key":"zoi240126r7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/jurban\/jti072","article-title":"Attitudes and practices regarding the use of methadone in US state and federal prisons.","volume":"82","author":"Rich","year":"2005","journal-title":"J Urban Health"},{"issue":"1-2","key":"zoi240126r8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.drugalcdep.2009.06.015","article-title":"Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey.","volume":"105","author":"Nunn","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi240126r9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/08897077.2011.611460","article-title":"Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions.","volume":"33","author":"Friedmann","year":"2012","journal-title":"Subst Abus"},{"issue":"12","key":"zoi240126r10","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1377\/hlthaff.2017.0890","article-title":"Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine.","volume":"36","author":"Krawczyk","year":"2017","journal-title":"Health Aff (Millwood)"},{"issue":"9","key":"zoi240126r11","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jamainternmed.2018.3504","article-title":"Implementing opioid agonist treatment in correctional facilities.","volume":"178","author":"Fiscella","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"1","key":"zoi240126r13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40352-021-00143-9","article-title":"The impact of the opioid crisis on U.S. state prison systems.","volume":"9","author":"Scott","year":"2021","journal-title":"Health Justice"},{"key":"zoi240126r14","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"10118","key":"zoi240126r15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"zoi240126r16","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/S0140-6736(17)33194-X","article-title":"Effects of opiate substitution treatment on mortality for opioids users: a systematic review and meta-analysis.","volume":"390","author":"Ma","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"zoi240126r17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi240126r18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/00258024221118971","article-title":"A meta-analysis on the effects of incarceration-based opioid substitution treatment.","volume":"63","author":"Boks\u00e1n","year":"2023","journal-title":"Med Sci Law"},{"key":"zoi240126r19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jsat.2018.12.003","article-title":"Effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review.","volume":"99","author":"Moore","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"zoi240126r20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/SAR","article-title":"Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions.","volume":"7","author":"Sharma","year":"2016","journal-title":"Subst Abuse Rehabil"},{"key":"zoi240126r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109254","article-title":"Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder.","volume":"231","author":"Evans","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"zoi240126r22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/add.v118.3","article-title":"Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.","volume":"118","author":"Lim","year":"2023","journal-title":"Addiction"},{"issue":"5","key":"zoi240126r23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038335","article-title":"Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners.","volume":"7","author":"Springer","year":"2012","journal-title":"PLoS One"},{"issue":"13","key":"zoi240126r24","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders.","volume":"374","author":"Lee","year":"2016","journal-title":"N Engl J Med"},{"key":"zoi240126r25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.drugalcdep.2014.05.011","article-title":"A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry.","volume":"142","author":"Gordon","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"zoi240126r26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugalcdep.2016.11.037","article-title":"A randomized clinical trial of buprenorphine for prisoners: findings at 12-months post-release.","volume":"172","author":"Gordon","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"9991","key":"zoi240126r27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0140-6736(14)62338-2","article-title":"Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial.","volume":"386","author":"Rich","year":"2015","journal-title":"Lancet"},{"key":"zoi240126r28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drugalcdep.2017.11.023","article-title":"A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: findings at 12 months post-release.","volume":"184","author":"Brinkley-Rubinstein","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"zoi240126r29","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/add.2014.109.issue-8","article-title":"The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study.","volume":"109","author":"Degenhardt","year":"2014","journal-title":"Addiction"},{"key":"zoi240126r30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jsat.2017.04.010","article-title":"Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.","volume":"85","author":"Friedmann","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"43","key":"zoi240126r32","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.15585\/mmwr.mm6643e1","article-title":"Deaths involving fentanyl, fentanyl analogs, and U-47700\u201410 states, July-December 2016.","volume":"66","author":"O\u2019Donnell","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"zoi240126r36","doi-asserted-by":"publisher","DOI":"10.1056\/CAT.19.1118","article-title":"Using data to guide action in response to the public health crisis of opioid overdoses.","volume":"1","author":"Bharel","year":"2020","journal-title":"NEJM Catal"},{"issue":"10","key":"zoi240126r38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"issue":"4","key":"zoi240126r42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research.","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"zoi240126r43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jclinepi.2008.08.007","article-title":"Methods for estimating confidence intervals in interrupted time series analyses of health interventions.","volume":"62","author":"Zhang","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"zoi240126r44","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100419","article-title":"Post-incarceration outcomes of a comprehensive statewide correctional MOUD program: a retrospective cohort study.","volume":"18","author":"Martin","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"4","key":"zoi240126r45","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40429-019-00283-x","article-title":"Medications for opioid use disorder among incarcerated individuals: a review of the literature and focus on patient preference.","volume":"6","author":"Puglisi","year":"2019","journal-title":"Curr Addict Rep"},{"issue":"1","key":"zoi240126r46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13722-019-0166-0","article-title":"Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.","volume":"14","author":"Velasquez","year":"2019","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"zoi240126r47","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/08897077.2022.2060448","article-title":"Medications for opioid use disorder in state prisons: perspectives of formerly incarcerated persons.","volume":"43","author":"Treitler","year":"2022","journal-title":"Subst Abus"},{"key":"zoi240126r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108690","article-title":"Treatment preference for opioid use disorder among people who are incarcerated.","volume":"137","author":"Kaplowitz","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"zoi240126r50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-071867","article-title":"Burden of opioid toxicity death in the fentanyl-dominant era for people who experience incarceration in Ontario, Canada, 2015-2020: a whole population retrospective cohort study.","volume":"13","author":"Butler","year":"2023","journal-title":"BMJ Open"},{"key":"zoi240126r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.208971","article-title":"Fatal and nonfatal opioid overdose risk following release from prison: a retrospective cohort study using linked administrative data.","volume":"147","author":"Hartung","year":"2023","journal-title":"J Subst Use Addict Treat"},{"issue":"4","key":"zoi240126r52","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1108\/IJPH-12-2022-0080","article-title":"Prevalence and characteristics of mental and physical disorders among female prisoners: a mixed-methods systematic review.","volume":"19","author":"Friestad","year":"2023","journal-title":"Int J Prison Health"},{"issue":"4","key":"zoi240126r56","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","article-title":"Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system.","volume":"75","author":"Green","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"zoi240126r12","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences, Engineering, and Medicine","year":"2019"},{"key":"zoi240126r31","unstructured":"Centers for Disease Control and Prevention. Drug Overdose Mortality by State. CDC National Center for Health Statistics website. Published March 1, 2022. Accessed July 19, 2022. https:\/\/www.cdc.gov\/nchs\/pressroom\/sosmap\/drug_poisoning_mortality\/drug_poisoning.htm"},{"key":"zoi240126r33","unstructured":"Massachusetts Department of Public Health. An Assessment of Fatal and Nonfatal Opioid Overdoses in Massachusetts (2011\u20132015). August 16, 2017. Accessed August 2, 2022. https:\/\/www.mass.gov\/files\/documents\/2017\/08\/31\/legislative-report-chapter-55-aug-2017.pdf"},{"key":"zoi240126r34","unstructured":"Massachusetts Department of Public Health. Data Brief: Opioid-Related Overdose Deaths among Massachusetts Residents. June 2022. Accessed April 5, 2023. https:\/\/www.mass.gov\/doc\/opioid-related-overdose-deaths-among-ma-residents-june-2022\/download"},{"key":"zoi240126r35","unstructured":"Chapter 208: An Act for Prevention and Access to Appropriate Care and Treatment of Addiction, H 4742, 190th Leg (Mass 2018). August 9, 2018. Accessed December 19, 2023. https:\/\/malegislature.gov\/Laws\/SessionLaws\/Acts\/2018\/Chapter208"},{"key":"zoi240126r37","unstructured":"Massachusetts Department of Public Health. Public Health Data Warehouse (PHD) Technical Documentation. Mass.gov. Published February 22, 2022. Accessed June 2, 2023. https:\/\/www.mass.gov\/info-details\/public-health-data-warehouse-phd-technical-documentation"},{"key":"zoi240126r39","unstructured":"Petroni? S. MCI Framingham Will No Longer House Female Inmates from 4 Western Counties. Patch.com. October 13, 2014. Accessed March 6, 2023. https:\/\/patch.com\/massachusetts\/framingham\/mci-framingham-will-no-longer-house-female-inmates-4-western-counties-0"},{"key":"zoi240126r40","doi-asserted-by":"crossref","unstructured":"Burrell? C, Martin? P. State Denies Suffolk Sheriff\u2019s Claim That Framingham Women\u2019s Prison Is Closing. WGBH. October 11, 2019. Accessed March 6, 2023. https:\/\/www.wgbh.org\/news\/local-news\/2019\/10\/11\/state-denies-suffolk-sheriffs-claim-that-framingham-womens-jail-is-closing","DOI":"10.1002\/nba.30599"},{"key":"zoi240126r41","unstructured":"Massachusetts Executive Office of Public Safety and Security. Cross-Tracking System\u2014State & County Correctional Populations. Mass.gov. Published January 2, 2024. Accessed January 18, 2024. https:\/\/www.mass.gov\/info-details\/cross-tracking-system-state-county-correctional-populations"},{"key":"zoi240126r49","unstructured":"Massachusetts Department of Correction. Report on Costs and Outcomes of Medication-Assisted Treatment Programs Included in G.L. 127 \u00a7 17B. Massachusetts Department of Correction. December 2020. Accessed December 12, 2023. https:\/\/www.mass.gov\/doc\/2020-medication-assisted-treatment-programs-annual-reports\/download"},{"key":"zoi240126r53","unstructured":"Bronson? J, Stroop? J, Zimmer? S, Berzofsky? M. Drug Use, Dependence, and Abuse Among State Prisoners and Jail Inmates, 2007-2009. Bureau of Justice Statistics report. Revised August 10, 2020. Accessed May 14, 2021. https:\/\/www.bjs.gov\/content\/pub\/pdf\/dudaspji0709.pdf"},{"key":"zoi240126r54","unstructured":"Maruschak? LM, Bronson? J, Alper? M. Alcohol and Drug Use and Treatment Reported by Prisoners: Survey of Prison Inmates, 2016. Bureau of Justice Statistics report. July 13, 2021. Accessed April 25, 2022. https:\/\/bjs.ojp.gov\/library\/publications\/alcohol-and-drug-use-and-treatment-reported-prisoners-survey-prison-inmates"},{"key":"zoi240126r55","unstructured":"Maruschak? LM, Bronson? J, Alper? M. Indicators of Mental Health Problems Reported by Prisoners: Survey of Prison Inmates, 2016. Bureau of Justice Statistics report. June 2, 2021. Accessed May 10, 2022. https:\/\/bjs.ojp.gov\/library\/publications\/indicators-mental-health-problems-reported-prisoners-survey-prison-inmates"},{"key":"zoi240126r57","unstructured":"Chapter 69: An Act Relative to Criminal Justice Reform, S 2371, 190th Leg (Mass 2018). April 13, 2018. Accessed December 19, 2023. https:\/\/malegislature.gov\/Laws\/SessionLaws\/Acts\/2018\/Chapter208"},{"key":"zoi240126r58","unstructured":"Mass Gen Laws ch 265. Accessed December 19, 2023. https:\/\/malegislature.gov\/Laws\/GeneralLaws\/PartIV\/TitleI\/Chapter265"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2816405\/bovellammon_2024_oi_240126_1710514360.24998.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T15:36:23Z","timestamp":1710776183000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2816405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.2732","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]}}}